Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 27;36(30):7841–7851. doi: 10.1523/JNEUROSCI.0439-16.2016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Lawrenson et al.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License Creative Commons Attribution 4.0 International, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Figure 2. — Characterization of evoked CFPs. A, Effect of paired pulse stimulation on the peak-to-peak amplitude of the second response expressed as a percentage of the first control response (mean ± SEM). Number of animals included in each mean shown above each bar. B, Stimulus–response curve for CFPs evoked by ipsilateral hindlimb stimulation at multiples of threshold for a detectable response (mean ± SD). Number of animals included in each mean shown above each data point. C, Example of a complex spike (top trace, asterisk) and CFP (bottom trace) evoked by the same ipsilateral hindlimb stimulation (arrowhead). D, Effect of 3-AP treatment on the amplitude of evoked fields (blue, n = 3) compared with saline controls (black, n = 2). Two-way ANOVA: interaction, F_(8,27) = 3.36, p = 0.0084; drug, F_(1,27) = 23.97, p < 0.0001; time, F_(8,27) = 4.59, p = 0.0013. Bonferroni's post hoc tests comparing 3-AP with control at each time point, **p < 0.01, ***p < 0.001. Drug or saline administered at time 0. E, Effect of 3-AP treatment on 200–300 Hz power of LFP (blue, n = 3) compared with saline controls (black, n = 2). Two-way ANOVA: interaction, F_(8,27) = 5.08, p = 0.0006; drug, F_(1,27) = 13.30, p = 0.0011; time, F_(8,27) = 4.55, p = 0.0013. Bonferroni's post hoc tests comparing 3-AP with control at each time point, ***p < 0.001. Drug or saline administered at time 0. F, Spectrograms derived from an example case (animal GRF) showing change in power in ∼200–300 Hz frequency bandwidth after application of 3-AP (bottom) in contrast to saline (top). Arrowhead, Time of delivery of saline or drug.